Literature DB >> 24415000

Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002.

Gabriele Calaminus1, Wolfgang Dörffel, Katja Baust, Carmen Teske, Marianne Riepenhausen, Jürgen Brämswig, Hans-Henning Flechtner, Susanne Singer, Andreas Hinz, Günther Schellong.   

Abstract

PURPOSE: The purpose of this study was to cross-sectionally assess quality of life (QoL) in survivors of childhood Hodgkin's disease (HD) in a cohort treated for HD in the successive German-Austrian therapy studies HD-78, HD-82, HD-85, HD-87, HD-90, HD-95, respectively, in accordance with the HD-Interval-Treatment recommendation between 1978 and 2002. PATIENTS AND METHODS: Data from QoL questionnaires were provided by 1,202 (66 %) of 1,819 invited survivors. These included the EORTC QLQ-C30 and socio-demographic variables. Data of a homogenous sub-sample (n = 725) defined by age (21-41 years) and event- free-survival (no progress, relapse or secondary malignancies) were compared to an age-adjusted German reference sample (n = 659).
RESULTS: While the global and physical QoL scores were comparable to those of the general population, survivors' mean scores were more than 10 points lower on the EORTC QLQ-C30 scales "Emotional" and "Social Functioning". On the symptom scales, higher mean scores, exceeding 10 points, were obtained for the scales "Fatigue" and "Sleep". In general, there was a gender effect showing lower functioning and higher symptom levels in women, most prominently in the group of young women (21-25 years). The results within the group of HD survivors could not be associated with the time since treatment, the age of HD survivors at diagnosis or the extent of therapy burden.
CONCLUSION: Clinicians engaged in follow-up care should be sensitive to aspects of fatigue and related (emotional) symptoms in HD childhood cancer survivors and encourage their patients to seek further support if needed.

Entities:  

Mesh:

Year:  2014        PMID: 24415000     DOI: 10.1007/s00520-013-2114-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  28 in total

1.  The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence.

Authors:  J H Brämswig; U Heimes; E Heiermann; W Schlegel; E Nieschlag; G Schellong
Journal:  Cancer       Date:  1990-03-15       Impact factor: 6.860

Review 2.  Quality of life in survivors of childhood cancer: a systematic review of the literature (2001-2008).

Authors:  Janette McDougall; Miranda Tsonis
Journal:  Support Care Cancer       Date:  2009-06-02       Impact factor: 3.603

3.  Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group.

Authors:  G Schellong
Journal:  Baillieres Clin Haematol       Date:  1996-09

4.  [Reducing radiation dosage to 20-30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood. A report of the cooperative DAL-HD-87 therapy study].

Authors:  G Schellong; I Hörnig-Franz; B Rath; J Ritter; M Riepenhausen; H Kabisch; B Goldschmitt-Wuttge; P Schmidt; D Niethammer; G Gaedicke
Journal:  Klin Padiatr       Date:  1994 Jul-Aug       Impact factor: 1.349

5.  Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.

Authors:  Günther Schellong; Marianne Riepenhausen; Christian Bruch; Stefan Kotthoff; Johannes Vogt; Tobias Bölling; Karin Dieckmann; Richard Pötter; Achim Heinecke; Jürgen Brämswig; Wolfgang Dörffel
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

Review 6.  A narrative review summarizing the state of the evidence on the health-related quality of life among childhood cancer survivors.

Authors:  Mary Ann Cantrell
Journal:  J Pediatr Oncol Nurs       Date:  2010-09-14       Impact factor: 1.636

7.  Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.

Authors:  W Dörffel; H Lüders; U Rühl; M Albrecht; H Marciniak; R Parwaresch; R Pötter; G Schellong; E-W Schwarze; L Wickmann
Journal:  Klin Padiatr       Date:  2003 May-Jun       Impact factor: 1.349

8.  The Challenge of Pediatric Hodgkin's Disease-Where is the Balance Between Cure and Long-Term Toxicity?: A report of the West German multicenter studies DAL-HD-78, DAL-HD-82 and DAL-HD-85.

Authors:  J H Brämswig; I Höornig-Franz; M Riepenhausen; G Schellong
Journal:  Leuk Lymphoma       Date:  1990

9.  Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study.

Authors:  Lonnie K Zeltzer; Qian Lu; Wendy Leisenring; Jennie C I Tsao; Christopher Recklitis; Gregory Armstrong; Ann C Mertens; Leslie L Robison; Kirsten K Ness
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

10.  Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG).

Authors:  J U Rüffer; H Flechtner; P Tralls; A Josting; M Sieber; B Lathan; V Diehl
Journal:  Eur J Cancer       Date:  2003-10       Impact factor: 9.162

View more
  10 in total

1.  Consider family history. In reply.

Authors:  Günther Schellong; Jürgen Brämswig
Journal:  Dtsch Arztebl Int       Date:  2014-05-30       Impact factor: 5.594

Review 2.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

3.  Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma.

Authors:  AnnaLynn M Williams; Sedigheh Mirzaei Salehabadi; Mengqi Xing; Nicholas S Phillips; Matthew J Ehrhardt; Rebecca Howell; Yutaka Yasui; Kevin C Oeffinger; Todd Gibson; Eric J Chow; Wendy Leisenring; Deokumar Srivastava; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull
Journal:  Blood       Date:  2022-05-19       Impact factor: 25.476

4.  Quality of life amongst lymphoma survivors in a developing country.

Authors:  Diana L C Ng; Y C Leong; Gin Gin Gan
Journal:  Support Care Cancer       Date:  2016-07-26       Impact factor: 3.603

Review 5.  Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care.

Authors:  Justine M Kahn; Kara M Kelly
Journal:  Pediatr Blood Cancer       Date:  2018-03-30       Impact factor: 3.167

6.  Fatigue in adolescent and adult survivors of non-CNS childhood cancer: a report from project REACH.

Authors:  Natasha N Frederick; Lisa Kenney; Lynda Vrooman; Christopher J Recklitis
Journal:  Support Care Cancer       Date:  2016-04-27       Impact factor: 3.603

7.  Severe fatigue after treatment for childhood cancer.

Authors:  Sylvia van Deuren; Amilie Boonstra; Eline van Dulmen-den Broeder; Nicole Blijlevens; Hans Knoop; Jacqueline Loonen
Journal:  Cochrane Database Syst Rev       Date:  2020-03-03

Review 8.  Health-related quality of life in Hodgkin lymphoma: a systematic review.

Authors:  Nadine Linendoll; Tully Saunders; Rebecca Burns; Jonathan D Nyce; Kristen B Wendell; Andrew M Evens; Susan K Parsons
Journal:  Health Qual Life Outcomes       Date:  2016-07-29       Impact factor: 3.186

Review 9.  The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice?

Authors:  Jamie E Flerlage; Monika L Metzger; Nickhill Bhakta
Journal:  Blood       Date:  2018-06-12       Impact factor: 25.476

Review 10.  Recommendations for the surveillance of cancer-related fatigue in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Authors:  Salome Christen; Katharina Roser; Renée L Mulder; Anica Ilic; Hanne C Lie; Jacqueline J Loonen; Anneli V Mellblom; Leontien C M Kremer; Melissa M Hudson; Louis S Constine; Roderick Skinner; Katrin Scheinemann; Jordan Gilleland Marchak; Gisela Michel
Journal:  J Cancer Surviv       Date:  2020-08-25       Impact factor: 4.442

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.